S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
S&P 500   4,577.10
DOW   34,639.79
QQQ   389.91
NASDAQ:EXEL

Exelixis Stock Forecast, Price & News

$16.48
+0.08 (+0.49%)
(As of 12/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.21
$16.72
50-Day Range
$16.40
$21.88
52-Week Range
$16.19
$25.77
Volume
1.34 million shs
Average Volume
2.04 million shs
Market Capitalization
$5.21 billion
P/E Ratio
32.31
Dividend Yield
N/A
Beta
0.94
30 days | 90 days | 365 days | Advanced Chart
Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.


Exelixis logo

About Exelixis

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.

Headlines

Exelixis (NASDAQ:EXEL) Coverage Initiated at Piper Sandler
November 19, 2021 |  americanbankingnews.com
Notable Exelixis Insider Trades $2.3M In Company Stock
November 18, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXEL
CUSIP
30161Q10
Employees
773
Year Founded
1994

Sales & Book Value

Annual Sales
$987.54 million
Cash Flow
$0.38 per share
Book Value
$6.06 per share

Profitability

Net Income
$111.78 million
Pretax Margin
16.29%

Debt

Price-To-Earnings

Miscellaneous

Free Float
305,956,000
Market Cap
$5.21 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/09/2022

Social Links


MarketRank

Overall MarketRank

2.95 out of 5 stars

Medical Sector

24th out of 1,391 stocks

Biological Products, Except Diagnostic Industry

3rd out of 202 stocks

Analyst Opinion: 4.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 3.1 5 -4 -3 -2 -1 -












Exelixis (NASDAQ:EXEL) Frequently Asked Questions

Is Exelixis a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Exelixis stock.
View analyst ratings for Exelixis
or view top-rated stocks.

How has Exelixis' stock been impacted by Coronavirus?

Exelixis' stock was trading at $17.32 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EXEL stock has decreased by 4.8% and is now trading at $16.48.
View which stocks have been most impacted by COVID-19
.

When is Exelixis' next earnings date?

Exelixis is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Exelixis
.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by $0.07. Exelixis had a trailing twelve-month return on equity of 8.27% and a net margin of 13.10%. During the same quarter in the prior year, the firm earned ($0.10) earnings per share.
View Exelixis' earnings history
.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.35 billion, compared to the consensus revenue estimate of $1.39 billion.

What price target have analysts set for EXEL?

11 analysts have issued 12 month price targets for Exelixis' stock. Their forecasts range from $26.00 to $52.00. On average, they expect Exelixis' stock price to reach $33.10 in the next year. This suggests a possible upside of 100.8% from the stock's current price.
View analysts' price targets for Exelixis
or view top-rated stocks among Wall Street analysts.

Who are Exelixis' key executives?

Exelixis' management team includes the following people:

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

32 employees have rated Exelixis CEO Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among Exelixis' employees.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (10.08%), Renaissance Technologies LLC (5.55%), Farallon Capital Management LLC (3.05%), Polar Capital Holdings Plc (1.29%), Geode Capital Management LLC (1.27%) and Stephens Investment Management Group LLC (1.09%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends for Exelixis
.

Which institutional investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Farallon Capital Management LLC, Balyasny Asset Management LLC, Balyasny Asset Management LLC, American Century Companies Inc., Renaissance Technologies LLC, Assenagon Asset Management S.A., and Sargent Investment Group LLC. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Patrick J Haley, Peter Lamb, Stelios Papadopoulos, and Vincent T Marchesi.
View insider buying and selling activity for Exelixis
or view top insider-selling stocks.

Which institutional investors are buying Exelixis stock?

EXEL stock was purchased by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., Janus Henderson Group PLC, Polar Capital Holdings Plc, Krensavage Asset Management LLC, Two Sigma Advisers LP, Allianz Asset Management GmbH, Dimensional Fund Advisors LP, and Marshall Wace LLP.
View insider buying and selling activity for Exelixis
or or view top insider-buying stocks.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $16.48.

How much money does Exelixis make?

Exelixis has a market capitalization of $5.21 billion and generates $987.54 million in revenue each year. The biotechnology company earns $111.78 million in net income (profit) each year or $0.51 on an earnings per share basis.

How many employees does Exelixis have?

Exelixis employs 773 workers across the globe.

When was Exelixis founded?

Exelixis was founded in 1994.

What is Exelixis' official website?

The official website for Exelixis is www.exelixis.com.

Where are Exelixis' headquarters?

Exelixis is headquartered at 1851 Harbor Bay Parkway, Alameda CA, 94502.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at (650) 837-7000, via email at [email protected], or via fax at 650-837-8300.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.